Results 301 to 310 of about 427,029 (392)

Correction: Stroma-driven horizontal transfer of TCA-related proteins mediates metabolic plasticity and Imatinib resistance in chronic myeloid leukemia. [PDF]

Cell Commun Signal
Chroscicki P, Kasak N, Dymkowska D, Turos-Korgul L, Cysewski D, Chumak V, Stepnik D, Kusio-Kobialka M, Kominek A, Lebiedzinska-Arciszewska M, Krop A, Szczepanowska J, Wieckowski M, Stoklosa T, Zablocki K, Piwocka K.   +15 more
europepmc   +1 more source

Modern Therapy of Chronic Myeloid Leukemia

, 2013
Maya M. Zaharieva, G. Amudov, Spiro Konstantinov, Liang Ma   +3 more
openalex   +2 more sources

Myelomastocytic transformation in chronic myeloid leukemia blast phase: A case report. [PDF]

J Hematop
Al-Mashdali AF, Ibrahim F, Kohla S, Ganwo I, Akiki S, Abdulgayoom M, Yassin MA.   +6 more
europepmc   +1 more source

Efficacy and safety of bosutinib vs imatinib in Indian and non-Indian patients with newly diagnosed chronic phase chronic myeloid leukemia: Subgroup analysis from the BELA trial

, 2018
Hemant Malhotra, Alpesh M. Maru, Navin Khattry, M. V. Ramanan, Eric Leip, Rocco J. Crescenzo, Carlo Gambacorti‐Passerini, Jörge E. Cortes   +7 more
openalex   +1 more source

Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study

British Journal of Haematology, EarlyView.
Summary Allogeneic haematopoietic stem cell transplantation (ASCT) is a curative treatment for acute myeloid leukaemia (AML) but carries a high risk of gonadotoxicity. Ovarian tissue cryopreservation (OTC) offers a fertility preservation option, yet its safety in AML remains uncertain due to the risk of leukaemic cell reintroduction. The FERTILAM pilot
Augustin Boudry, Florian Chevillon, Alice Marceau‐Renaut, Thorsten Braun, Thomas Boyer, Nathalie Helevaut, Elise Fournier, Sandrine Geffroy, Nicolas Boissel, Emmanuelle Clappier, Claude Preudhomme, Nicolas Duployez, Catherine Poirot, Laurène Fenwarth   +13 more
wiley   +1 more source

Cardiovascular Disease in Patients With Chronic Myeloid Leukemia: JACC: CardioOncology State-of-the-Art Review. [PDF]

JACC CardioOncol
Aghel N, Lipton JH.
europepmc   +1 more source

Hypomethylating agents in vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic syndrome (VEXAS): A systematic review

British Journal of Haematology, EarlyView.
Summary VEXAS syndrome (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) is an X‐linked, systemic, haemato‐inflammatory syndrome caused by somatic mutations in the UBA1 gene. No standardized treatment guidelines exist, but evidence is emerging that treatment with hypomethylating agents (HMAs) can induce improvement of the inflammatory symptoms,
Fieke W. Hoff, Roochi Trikha, Emma M. Groarke, Bhavisha A. Patel   +3 more
wiley   +1 more source

Chronic Myeloid Leukemia

, 2012
openaire   +2 more sources

AKI in chronic myeloid leukemia: remember lysozyme-induced nephropathy. [PDF]

J Bras Nefrol
Santos A, Marques N, Pestana R.
europepmc   +1 more source

HSD127 Real-World Patterns of Tyrosine Kinase Inhibitor (TKI) Discontinuation and Reinitiation in Chronic Myeloid Leukemia (CML) Patients in the United States [PDF]

Jyotirmoy Sarker, Aaron N. Winn
openalex   +1 more source